Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison
Authors:
Open Access
- 21 May 2024
- journal article
- research article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 212, 111717
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly and Company
This publication has 17 references indexed in Scilit:
- Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysiseClinicalMedicine, 2023
- Therapeutic inertia related to the injectable glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary careDiabetes, Obesity and Metabolism, 2023
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2022
- Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparisonDiabetes, Obesity and Metabolism, 2022
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesNew England Journal of Medicine, 2021
- Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential FeaturesClinical Drug Investigation, 2019
- Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?Diabetes/Metabolism Research and Reviews, 2018
- The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting AnalogsDiabetes Technology & Therapeutics, 2018
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trialThe Lancet Diabetes & Endocrinology, 2018
- The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJournal of Clinical Epidemiology, 1997